Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4653162 | 0.97 | ALDH1A1 (0.43) | ALDH1A1TSHRTDP1HSD17B10LMNA | |
| SCHEMBL10837533 | 0.86 | CYP4F2 (0.40) | ALDH1A1TSHRTDP1HSD17B10LMNA | |
| SCHEMBL9015631 | 0.84 | ALDH1A1 (0.36) | ALDH1A1TSHRTDP1HSD17B10LMNA | |
| SCHEMBL6656497 | 0.84 | ALDH1A1 (0.36) | ALDH1A1TSHRTDP1HSD17B10LMNA | |
| SCHEMBL5570447 | 0.81 | CYP4F2 (0.37) | ALDH1A1TSHRCYP4F2CYP4A11 | |
| SCHEMBL5570450 | 0.81 | ALDH1A1 (0.41) | ALDH1A1TSHRTDP1HSD17B10LMNA | |
| SCHEMBL28423843 | 0.80 | CYP4F2 (0.43) | ALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL27805166 | 0.78 | CYP4F2 (0.42) | ALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL1417855 | 0.77 | ALDH1A1 (0.43) | ALDH1A1TSHRTDP1HSD17B10LMNA | |
| SCHEMBL6365280 | 0.77 | ALDH1A1 (0.46) | ALDH1A1TSHRTDP1CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024249-A1 | ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A METHYL HYDROGEN FUMARATE PRODRUG | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2024-01-25 | — | — | US | disclosed |
| EP-2654463-B1 | ANTIOXIDANTS IN FISH OIL POWDER AND TABLETS | OMEGATRI AS (NO) | 2018-05-30 | — | — | EP | disclosed |
| EP-1586295-B1 | Cosmetic composition for skin, lips and / or nails. | L'ORÉAL (FR) | 2017-05-17 | — | — | EP | disclosed |
| US-20170035714-A1 | Oral Dosage forms having a High Loading of a Gabapentin Prodrug | ARBOR PHARMACEUTICALS, LLC | 2017-02-09 | — | — | US | disclosed |
| US-20140056973-A1 | Oral Dosage Forms Having a High Loading of a Methyl Hydrogen Fumarate Prodrug | XENOPORT, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| WO-2014031897-A1 | ORAL DOSAGE FORMS HAVING A HIGH LOADING OF (N,N- DIETHYLCARBAMOYL)METHYL METHYL|(2E)BUT-2-ENE-1,4-DIOATE | XENOPORT, INC. (US) | 2014-02-27 | — | — | WO | disclosed |
| EP-2654463-A2 | ANTIOXIDANTS IN FISH OIL POWDER AND TABLETS | Omegatri AS (NO) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012085671-A2 | ANTIOXIDANTS IN FISH OIL POWDER AND TABLETS | OMEGATRI AS (NO) | 2012-06-28 | — | — | WO | disclosed |
| US-20120156296-A1 | ANTIOXIDANTS IN FISH OIL POWDER AND TABLETS | OMEGATRI AS (NO) | 2012-06-21 | — | — | US | disclosed |
| EP-2403481-A1 | ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A GABAPENTIN PRODRUG | XenoPort, Inc. (US) | 2012-01-11 | — | — | EP | disclosed |
| EP-0765157-A1 | PELLETS | DUMEX-ALPHARMA A/S (DK) | 1997-04-02 | — | — | EP | disclosed |
| WO-1995034291-A1 | PELLETS | DUMEX-ALPHARMA A/S (DK) | 1995-12-21 | — | — | WO | disclosed |
| US-4609741-A | CURING AGENTS FOR EPOXIDES | CIBA-GEIGY CORPORATION (US) | 1986-09-02 | — | — | US | disclosed |
| US-4480105-A | PHOTOCROSSLINKING POLYMERS | CIBA-GEIGY CORPORATION (US) | 1984-10-30 | — | — | US | disclosed |
| US-4363917-A | SENSITIZERS FOR PHOTOCROSSLINKABLE POLYMERS; PHOTOPOLYMERIZATION INITIATORS | CIBA-GEIGY CORPORATION (US) | 1982-12-14 | — | — | US | disclosed |
| US-4160081-A | Imidyl- and isoimidyl-phthalic anhydrides, process for their manufacture and their use for curing epoxide resins | CIBA-GEIGY CORPORATION (US) | 1979-07-03 | — | — | US | disclosed |
| US-4158662-A | STORAGE STABLE MOLDING MATERIAL | CIBA-GEIGY CORPORATION (US) | 1979-06-19 | — | — | US | disclosed |
| US-4140703-A | CURING AGENTS FOR POLYEPOXIDES | CIBA-GEIGY CORPORATION (US) | 1979-02-20 | — | — | US | disclosed |
| US-4131613-A | CURING AGENTS FOR EPOXIDE RESINS | CIBA-GEIGY CORPORATION (US) | 1978-12-26 | — | — | US | disclosed |
| US-3979393-A | Imidyl- and isoimidyl-phthalic anhydrides, process for their manufacture and their use for curing epoxide resins | CIBA-GEIGY CORPORATION (US) | 1976-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024249-A1 | ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A METHYL HYDROGEN FUMARATE PRODRUG | FH, MGMT, CYP4F2 | ALDH1A1 1240/4885TSHR 4391/4885TDP1 2155/4885 |
| US-20170035714-A1 | Oral Dosage forms having a High Loading of a Gabapentin Prodrug | GABRE, GABRP, GABRG1 | ALDH1A1 950/4885TSHR 3881/4885TDP1 2298/4885 |
| US-20140056973-A1 | Oral Dosage Forms Having a High Loading of a Methyl Hydrogen Fumarate Prodrug | FH, MGMT, CYP4F2 | ALDH1A1 1240/4885TSHR 4391/4885TDP1 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.